Is all ALS genetic?
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published June 22, 2017.
Article Versions
- Previous version (June 22, 2017 - 09:19).
- You are viewing the most recent version of this article.
Author Disclosures
- Peter M. Andersen, MD, PhD
- Peter M. Andersen, MD, PhD
Commercial: Advisory board for Biogen Idec for clinical trial of new drugs relevant to the genetics of ALS. Received compensation. Advisory board for Orphazyme for clinical trial of a new drug relevant to the genetics of ALS. Received compensation.
NONE
Commercial: funding for travel to advisory board meetings for Biogen Idec and Orphazyme Non-profit: funding for travel to meetings for non-for profit meetings for patient organizations in the Norway and Sweden.
Member of the Editorial Advisory board for the journal “Amyotrophic lateral sclerosis and Frontotemporal Degeneration”, since 2007. (No economic compensation given)
NONE
NONE
NONE
NONE
Received compensation for speeches to non-for profit patient organizations in Sweden, Norway and Denmark.
NONE
NONE
NONE
RESEARCH GRANTS: The Swedish Medical Research Council, since 2007 (multiple)(#521-2012- 3167) County of Vasterbotten, Sweden (#7002678, #7002829) Ume? University Research Foundation (#2.1.12-1605-14)
NONE
The Swedish Brain Research foundation, annually since 1998. (#2016- 0303). Swedish Brain Power Society, annually 2004-2015. The Swedish patients organization (many years, many smaller grants). The Knut and Alice Wallenberg Foundation (KAW): Project grant 2013- 2017 (KAW #2012.0091) The Knut and Alice Wallenberg Foundation Clinical Scholarship 2016- 2020 (KAW #2014.0305)
NONE
NONE
NONE
NONE
NONE
NONE
- Correspondence to Dr. Andersen: Peter.Andersen{at}umu.se
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Views & Reviews
C9orf72 and the Care of the Patient With ALS or FTDProgress and Recommendations After 10 YearsJennifer Roggenbuck et al.Neurology: Genetics, December 21, 2020 -
Articles
Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseasesWouter van Rheenen, Marka van Blitterswijk, Mark H.B. Huisman et al.Neurology, July 25, 2012 -
Article
Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disordersSerena Lattante, Stéphanie Millecamps, Giovanni Stevanin et al.Neurology, August 06, 2014 -
Article
Multiparametric MRI study of ALS stratified for the C9orf72 genotypePeter Bede, Arun L.W. Bokde, Susan Byrne et al.Neurology, June 14, 2013